Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
How Has the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Performance Trended Historically, And What Lies Ahead?
The market size of chronic inflammatory demyelinating polyneuropathy (CIDP) has seen robust growth lately. The market, which was valued at $2.10 billion in 2024, is projected to rise to $2.38 billion in 2025. This accounts for a compound annual growth rate (CAGR) of 8.4%. Factors such as the growing elderly population, advancements in treatment strategies, heightened public awareness and early detection, progress in the field of immunology and autoimmune research, and increased incidences of autoimmune disorders have played significant roles in the market’s growth during the historical period.
The market for chronic inflammatory demyelinating polyneuropathy (CIDP) is forecasted to witness a significant surge in the coming years, reaching a valuation of $3.11 billion in 2029, growing at a compound annual growth rate (CAGR) of 8.1%. The predicted growth in this forecast period can be linked to factors such as the escalating global elderly population, an intensified focus on uncommon diseases and autoimmune disorders, improved access to healthcare services, patient advocacy and awareness initiatives, and enhanced healthcare infrastructure. The forecast period is also likely to see some major trends, such as a rising occurrence of chronic inflammatory demyelinating polyneuropathy, progressive developments in treatment choices, accelerating research and development activities, the emergence of biosimilar therapies, and the evolution of personalized medicine strategies.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21144&type=smp
What Are the Primary Drivers Supporting the Market Growth of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
The growth of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is projected to be spurred by the ongoing increase in healthcare spending. The upsurge in spending on healthcare can be attributed to a rise in investments in the medical infrastructure, amplified demand for technologically advanced treatments, expanded insurance coverage, as well as initiatives by the government to boost healthcare accessibility. High levels of spending on healthcare facilitate access to state-of-the-art treatments, early detection, and superior handling of CIDP, which greatly improves patients’ outcomes and quality of life. For instance, the Office for National Statistics, a publicly administered department in the UK, reported in May 2024 that there was a substantial increase of 5.6% in overall healthcare spending in nominal terms between 2022 and 2023. This was a considerable escalation compared to the 0.9% growth seen in 2022. Thus, the rise in healthcare spending is a critical driver for the expansion of the CIDP market.
Which Primary Segments of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Are Driving Growth and Industry Transformations?
The chronic inflammatory demyelinating polyneuropathy (CIDP) market covered in this report is segmented –
1) By Treatment: Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, Other Treatments
2) By Route Of Administration: Intravenous, Oral, Other Routes Of Administration
3) By Diagnosis: Electrodiagnostic Testing, Nerve Conduction, Electromyography (EMG), Spinal Fluid Analysis, Other Diagnosis
4) By Distribution Channel: Hospitals, Pharmacies, Online Pharmacies, Specialty Clinics
5) By End User: Hospitals, Research Institutions, Homecare Settings
Subsegments:
1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy, High-Dose IVIG Therapy
2) By Corticosteroids: Oral Corticosteroids, Intravenous Corticosteroids
3) By Plasmapheresis: Single-Exchange Plasmapheresis, Multiple-Exchange Plasmapheresis
4) By Physiotherapy: Muscle Strengthening Exercises, Balance And Coordination Therapy
5) By Other Treatments: Immunosuppressive Agents, Monoclonal Antibodies
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21144&type=smp
Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?# Market?
North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2024. The regions covered in the chronic inflammatory demyelinating polyneuropathy (CIDP) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Most Significant Market Trends in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Major firms in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) sector are honing their focus on advancements like Intravenous Immunoglobulin (IVIG) therapy. This is in an effort to boost treatment efficacy, enhance patient experiences, and offer more specialized and effective immune regulation for CIDP management. IVIG therapy is an approach that administers a heavy dose of antibodies from healthy donors, aiming at moderating the immune system and mitigating inflammation in autoimmune disorders. For instance, in January 2024, Takeda Pharmaceutical Company Limited, a pharmaceutical corporation from Japan, won FDA approval for its IVIG therapy GAMMAGARD LIQUID for adults diagnosed with CIDP. This sanction permits its application as an initial treatment, commencing with an initial dosage and then followed by sustaining doses for long-term disease handling and enhancing neuromuscular function.
View the full report here:
What Parameters Are Used to Define the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder that causes progressive weakness and impaired sensory function due to nerve inflammation and demyelination. It results from the immune system attacking the myelin sheath of peripheral nerves, leading to muscle weakness, numbness, and coordination issues.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21144
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model